Zimmer & ISTO to commence human trials of Neocartilage graft:
This article was originally published in Clinica
Zimmer and ISTO Technologies have received investigational new drug (IND) approval in the US for Neocartilage, a living tissue-engineered graft for the repair of cartilage defects. The IND covers the restoration of joint function and relief of pain in the knee. The approval will allow the firms to proceed with human clinical trials of the product. Neocartilage was developed by St Louis, Missouri-based ISTO, which in 2002 granted exclusive marketing and distribution rights to Zimmer. The two companies have since collaborated on pre-clinical trials of the product. Neocartilage is a grown from juvenile chondrocytes (cartilage cells), using ISTO's proprietary cell-based platform technology.
You may also be interested in...
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.